News

Vascular Therapies completes $25 million private financing

Vascular Therapies completes $25 million private financing

Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, has announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company. Vascular Therapies plans to use the proceeds

Read More
Paragraf raises $60 million in Series B financing

Paragraf raises $60 million in Series B financing

Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations.  The round included

Read More
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition

Read More
NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders

NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round. The financing round was co-led by Ysios Capital and Forbion Growth and joined by

Read More
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study

Read More
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform

Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing

Read More
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, has announced that it has raised €19 million in the first close of a Series B financing, which was co-led by new investor CR-CP Life Science Fund,

Read More
VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector

VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector

VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our

Read More
BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc.

BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc.

BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds

Read More
Ventyx Biosciences announces key appointments and closing of $51m Series B financing

Ventyx Biosciences announces key appointments and closing of $51m Series B financing

Ventyx Biosciences, Inc. (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, has announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief

Read More
VORAGO Technologies announces low-cost and immediately available rad-tolerant hi-rel MCU for New Space, LEO market

VORAGO Technologies announces low-cost and immediately available rad-tolerant hi-rel MCU for New Space, LEO market

VORAGO Technologies (https://voragotech.com) has announced a product portfolio expansion to include a new radiation-tolerant Arm® Cortex-M0 MCU, VA10805, as a cost-competitive and high reliability solution for LEO, New Space, SmallSat and CubeSat markets. "As commercialization of space continues to grow, so does the need for reliable, affordable, and immediately available

Read More
Isorg raises €16 million in Series C financing

Isorg raises €16 million in Series C financing

Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund

Read More